Bone metastasis

Targeted therapy

Radium-223

Prostate cancer

Photodynamic therapy

Surgery

Alpha (finance)

Cancer research

Organic chemistry

Construct validity

Internal medicine

Cancer therapy

Oncology

Medicine

Chemistry

Cancer

Patient satisfaction

Current Radiopharmaceuticals

Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.

An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

An Overview of Targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth